Pleiotropic effects of pitavastatin.
Bottom Line: In addition to the direct effects of statins in reducing concentrations of atherogenic low density lipoprotein cholesterol (LDL-C), several studies have indicated that the beneficial effects of statins may be due to some of their cholesterol-independent, multiple (pleiotropic) effects which may differ between different members of the class.Pitavastatin is a novel synthetic lipophilic statin that has a number of pharmacodynamic and pharmacokinetic properties distinct from those of other statins, which may underlie its potential pleiotropic benefits in reducing cardiovascular risk factors.It is concluded that the diverse pleiotropic actions of pitavastatin may contribute to reducing cardiovascular morbidity and mortality beyond that achieved through LDL-C reduction.
Affiliation: Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montréal (IRCM) and University of Montréal, QC, Canada. Jean.Davignon@ircm.qc.caShow MeSH
Related in: MedlinePlus
Mentions: The effects of statins on endothelial cells are associated with significant reductions in coronary artery disease (CAD), cerebrovascular disease and peripheral artery disease , and improvements in markers of endothelial function are observed during clinical use of pitavastatin. Fasting and postprandial forearm blood flow increased significantly (P < 0.05) during post ischaemic reactive hyperaemia in patients with CAD following 6 months of treatment with pitavastatin, but not in controls (Figure 3) . Vasodilatation of the brachial artery was also increased after short term (2 weeks) treatment with pitavastatin in patients with primary hypercholesterolaemia. This increase was significantly greater in patients treated with pitavastatin (n= 37) than in those treated with atorvastatin (n= 34) after only 2 weeks of treatment (P < 0.05) and remained higher, although not significantly, in patients treated with pitavastatin for 3 months . Furthermore, improvements in endothelium-dependent flow-mediated vasodilatation have been shown following pitavastatin treatment in people who smoke (Figure 4), an effect likely to reflect protection of endothelial cells against oxidative stress .
Affiliation: Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montréal (IRCM) and University of Montréal, QC, Canada. Jean.Davignon@ircm.qc.ca